| Dr George Khoriaty, MD | |
|
800 Meadows Rd, Boca Raton, FL 33486-2304 | |
| (561) 391-1728 | |
| (561) 447-9352 |
| Full Name | Dr George Khoriaty |
|---|---|
| Gender | Male |
| Speciality | Interventional Radiology |
| Experience | 29 Years |
| Location | 800 Meadows Rd, Boca Raton, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295789188 | NPI | - | NPPES |
| 262920800 | Medicaid | FL | |
| 300137473 | Other | FL | RAILROAD MEDICARE |
| 25007 | Other | FL | BCBSFL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | ME0082636 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Boca Raton Regional Hospital | Boca raton, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mori Bean And Brooks Inc | 8820077878 | 633 |
News Archive
Scientists, health officials, and manufacturers already know that a chemical preservative found in some products, including cosmetics, is harmful to people and animals in high concentrations, but a new Brown University study in tadpoles reports that it can also interrupt neurological development even in very low concentrations.
A new study published on the preprint server bioRxiv in June 2020 reports some important findings that could shed light on this question. As the pandemic marches on, having claimed over 500,000 lives and caused well over 10 million infections to date, the task of defining and predicting factors that predispose to infectivity across species becomes ever more critical.
Researchers at Vanderbilt University Medical Center, in collaboration with Seaside Therapeutics in Cambridge, Mass., have achieved a milestone in the development of a potential new treatment for fragile X syndrome, the most common genetic cause of autism.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that additional results from its Phase 3 trial (SYMMETRYSM) of elesclomol in combination with paclitaxel in metastatic melanoma was presented at the Perspectives in Melanoma XIII Conference by Steven O'Day, M.D., principal investigator and Chief of Research and Director of the Melanoma Program at the Angeles Clinic in Santa Monica, California.
› Verified 1 days ago
| Entity Name | Radiology Associates Of South Florida Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699759183 PECOS PAC ID: 5799689659 Enrollment ID: O20031121000573 |
News Archive
Scientists, health officials, and manufacturers already know that a chemical preservative found in some products, including cosmetics, is harmful to people and animals in high concentrations, but a new Brown University study in tadpoles reports that it can also interrupt neurological development even in very low concentrations.
A new study published on the preprint server bioRxiv in June 2020 reports some important findings that could shed light on this question. As the pandemic marches on, having claimed over 500,000 lives and caused well over 10 million infections to date, the task of defining and predicting factors that predispose to infectivity across species becomes ever more critical.
Researchers at Vanderbilt University Medical Center, in collaboration with Seaside Therapeutics in Cambridge, Mass., have achieved a milestone in the development of a potential new treatment for fragile X syndrome, the most common genetic cause of autism.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that additional results from its Phase 3 trial (SYMMETRYSM) of elesclomol in combination with paclitaxel in metastatic melanoma was presented at the Perspectives in Melanoma XIII Conference by Steven O'Day, M.D., principal investigator and Chief of Research and Director of the Melanoma Program at the Angeles Clinic in Santa Monica, California.
› Verified 1 days ago
| Entity Name | Boca Radiology Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033163423 PECOS PAC ID: 2567354707 Enrollment ID: O20040325000185 |
News Archive
Scientists, health officials, and manufacturers already know that a chemical preservative found in some products, including cosmetics, is harmful to people and animals in high concentrations, but a new Brown University study in tadpoles reports that it can also interrupt neurological development even in very low concentrations.
A new study published on the preprint server bioRxiv in June 2020 reports some important findings that could shed light on this question. As the pandemic marches on, having claimed over 500,000 lives and caused well over 10 million infections to date, the task of defining and predicting factors that predispose to infectivity across species becomes ever more critical.
Researchers at Vanderbilt University Medical Center, in collaboration with Seaside Therapeutics in Cambridge, Mass., have achieved a milestone in the development of a potential new treatment for fragile X syndrome, the most common genetic cause of autism.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that additional results from its Phase 3 trial (SYMMETRYSM) of elesclomol in combination with paclitaxel in metastatic melanoma was presented at the Perspectives in Melanoma XIII Conference by Steven O'Day, M.D., principal investigator and Chief of Research and Director of the Melanoma Program at the Angeles Clinic in Santa Monica, California.
› Verified 1 days ago
| Entity Name | Mori Bean And Brooks Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093782070 PECOS PAC ID: 8820077878 Enrollment ID: O20040714001317 |
News Archive
Scientists, health officials, and manufacturers already know that a chemical preservative found in some products, including cosmetics, is harmful to people and animals in high concentrations, but a new Brown University study in tadpoles reports that it can also interrupt neurological development even in very low concentrations.
A new study published on the preprint server bioRxiv in June 2020 reports some important findings that could shed light on this question. As the pandemic marches on, having claimed over 500,000 lives and caused well over 10 million infections to date, the task of defining and predicting factors that predispose to infectivity across species becomes ever more critical.
Researchers at Vanderbilt University Medical Center, in collaboration with Seaside Therapeutics in Cambridge, Mass., have achieved a milestone in the development of a potential new treatment for fragile X syndrome, the most common genetic cause of autism.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that additional results from its Phase 3 trial (SYMMETRYSM) of elesclomol in combination with paclitaxel in metastatic melanoma was presented at the Perspectives in Melanoma XIII Conference by Steven O'Day, M.D., principal investigator and Chief of Research and Director of the Melanoma Program at the Angeles Clinic in Santa Monica, California.
› Verified 1 days ago
| Entity Name | Diagnostic Centers Of America, Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730125261 PECOS PAC ID: 0547174120 Enrollment ID: O20080223000067 |
News Archive
Scientists, health officials, and manufacturers already know that a chemical preservative found in some products, including cosmetics, is harmful to people and animals in high concentrations, but a new Brown University study in tadpoles reports that it can also interrupt neurological development even in very low concentrations.
A new study published on the preprint server bioRxiv in June 2020 reports some important findings that could shed light on this question. As the pandemic marches on, having claimed over 500,000 lives and caused well over 10 million infections to date, the task of defining and predicting factors that predispose to infectivity across species becomes ever more critical.
Researchers at Vanderbilt University Medical Center, in collaboration with Seaside Therapeutics in Cambridge, Mass., have achieved a milestone in the development of a potential new treatment for fragile X syndrome, the most common genetic cause of autism.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that additional results from its Phase 3 trial (SYMMETRYSM) of elesclomol in combination with paclitaxel in metastatic melanoma was presented at the Perspectives in Melanoma XIII Conference by Steven O'Day, M.D., principal investigator and Chief of Research and Director of the Melanoma Program at the Angeles Clinic in Santa Monica, California.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr George Khoriaty, MD Po Box 810969, Boca Raton, FL 33481-0969 Ph: (561) 447-9341 | Dr George Khoriaty, MD 800 Meadows Rd, Boca Raton, FL 33486-2304 Ph: (561) 391-1728 |
News Archive
Scientists, health officials, and manufacturers already know that a chemical preservative found in some products, including cosmetics, is harmful to people and animals in high concentrations, but a new Brown University study in tadpoles reports that it can also interrupt neurological development even in very low concentrations.
A new study published on the preprint server bioRxiv in June 2020 reports some important findings that could shed light on this question. As the pandemic marches on, having claimed over 500,000 lives and caused well over 10 million infections to date, the task of defining and predicting factors that predispose to infectivity across species becomes ever more critical.
Researchers at Vanderbilt University Medical Center, in collaboration with Seaside Therapeutics in Cambridge, Mass., have achieved a milestone in the development of a potential new treatment for fragile X syndrome, the most common genetic cause of autism.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that additional results from its Phase 3 trial (SYMMETRYSM) of elesclomol in combination with paclitaxel in metastatic melanoma was presented at the Perspectives in Melanoma XIII Conference by Steven O'Day, M.D., principal investigator and Chief of Research and Director of the Melanoma Program at the Angeles Clinic in Santa Monica, California.
› Verified 1 days ago
Dr. Anastasia Frances Barron, D.O. Radiology Medicare: Accepting Medicare Assignments Practice Location: 951 Nw 13th St Ste 1d, Boca Raton, FL 33486 Phone: 312-724-8477 | |
Dr. Ira J Braunschweig, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 951 Nw 13th St, Suite 1c, Boca Raton, FL 33486 Phone: 561-447-9341 Fax: 561-447-9352 | |
Dr. Craig Kolodziej, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 951 Nw 13th St, Suite 1c, Boca Radiology Group, Boca Raton, FL 33486 Phone: 561-447-9341 | |
Surya Vaidyanathan, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 800 Meadows Rd, Suite 1c, Boca Raton, FL 33486 Phone: 561-447-9341 | |
Dr. Thomas Jose Eluvathingal, M.D.,MB;BS Radiology Medicare: Accepting Medicare Assignments Practice Location: 3848 Fau Blvd Ste 305, Boca Raton, FL 33431 Phone: 561-455-3627 Fax: 305-243-4613 | |
Dr. Sabrina Yvette Saida, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 800 Meadows Rd, Boca Raton, FL 33486 Phone: 561-447-9341 Fax: 561-447-9352 | |
Dr. Edward Victor Grayson, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 3435 Windsor Pl, Boca Raton, FL 33496 Phone: 561-926-3230 |